Skip to Content

New Drug Approvals Archive - May 2003

May 2003

Iressa (gefitinib) Tablets

Date of Approval: May 5, 2003
Company: AstraZeneca
Treatment for: Non-Small Cell Lung Cancer

Iressa (gefitinib) is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific epidermal growth factor receptor (EGFR) gene mutations as detected by an FDA-approved test.

Velcade (bortezomib) for Injection

Date of Approval: May 13, 2003
Company: Millennium Pharmaceuticals
Treatment for: Multiple Myeloma

Velcade is an antineoplastic agent indicated for the treatment of multiple myeloma and mantle cell lymphoma.

New Drug Approvals Archive